Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Date:8/14/2008

m a preclinical study evaluating PCI-32765, an

orally available, selective inhibitor of Bruton's tyrosine kinase,

or Btk, in collagen induced arthritis, an established animal model

for rheumatoid arthritis (RA). Treatment of animals with advanced

disease, with PCI-32765 reduced inflammation and induced regression

of disease.

* Filed an investigational new drug (IND) application for PCI-27483, a

small molecule inhibitor of Factor VIIa being developed both for the

treatment of thrombotic complications of cancer and as an

anti-cancer agent.

* Plan to complete enrollment and evaluation of a Phase 1 trial in

normal volunteers with our Factor VIIa inhibitor, PCI-27483, in the

fourth quarter of calendar 2008.

* Plan to initiate a Phase 1 trial with our oral Btk inhibitor,

PCI-32765, in patients with recurrent B-cell lymphoma in the fourth

quarter of calendar 2008. This study is designed to evaluate safety

and efficacy using a novel pharmacodynamic biomarker.

* Plans are underway to design and conduct a pivotal Phase 3 trial

with motexafin gadolinium in patients with brain metastases from

non-small cell lung cancer receiving whole brain radiation and

stereotactic radiosurgery. This trial is anticipated to begin in the

first half of calendar 2009.

Conference Call and Webcast Details

The Company will hold a conference call today at 4:30 p.m. EDT to discuss fiscal 2008 year-end financial results and achievements and fiscal 2009 guidance. To participate in the conference call, please dial 800-497-0451 for domestic callers and 706-758-3306 for international callers and reference conference passcode 59146626. To access the live audio broadcast or the subsequent archived recording, log on to

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
2. Pharmacyclics Announces It Received Nasdaq Notification
3. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... September 16, 2014 CIRTEC Medical Systems’ ... Highley as CEO of CIRTEC. , “I am ... for the Company.” noted Brian Highley. “The company has ... sustaining strong organic growth over the past two years. ... continuing to improve and expand the services Cirtec offers ...
(Date:9/16/2014)... 16, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... completion of the Company,s Investor Day in ... irritable bowel syndrome (IBS) program, including its novel, ... In the keynote presentation, Mark Pimentel ...
(Date:9/16/2014)... Arizona (PRWEB) September 16, 2014 ... develops safe and effective products to treat patients ... use of a proprietary SPACE™ Technology Platform announced ... and President will present at the White Hat ... at the Hyatt Regency Phoenix. In addition, ...
(Date:9/16/2014)... BARBARA, Calif. , Sept. 16, 2014 /PRNewswire-iReach/ ... Strength index (BMSi) test identifies patients with bone ... cannot.  Over 160 million people worldwide are at ... detected by today,s standard bone strength test, the ... the 2014 American Society for Bone and Mineral ...
Breaking Biology Technology:Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3
... Jan. 4 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ... Annual,JPMorgan Healthcare Conference on Thursday, January 10, 2008 at ... held at the Westin St. Francis,Hotel in San Francisco., ... of Anadys,Pharmaceuticals, Inc., will present an update and overview ...
... 4 ARCA Discovery Inc., a privately held,biopharmaceutical ... other cardiovascular diseases, today announced Richard B.,Brewer, President ... 26th,Annual JPMorgan Healthcare Conference on Tuesday, January 8 ... Conference will be held January 7-10, 2008 at,the ...
... NEW YORK, Jan. 4 QED International ... a series of,20 underlying fund portfolios, today ... on Monday January 7, 2008, Alexion Pharmaceutical, ... Pharmaceutical, Inc. (Nasdaq: ASPV ) in,the ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference 2ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008 2QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction 2
(Date:9/16/2014)... tree species has its own bacterial identity. That,s the ... other institutions who studied the genetic fingerprints of bacteria ... island. , "This study demonstrates for the first time ... different ecological strategies possess very different microbial communities on ... former postdoctoral researcher in the UO,s Institute of Ecology ...
(Date:9/16/2014)... A complex web of interaction between viruses, bacteria, ... by a growing international collaboration between Matthew Sullivan, ... of Ecology and Evolutionary Biology and Steven Hallam ... Canada. , "Bacteria are drivers of nutrient ... said. "As the climate is changing, so are ...
(Date:9/16/2014)... extravagant, colorful tail feathers in courtship of a peahen. ... camera developed by an engineer at Washington University in ... choose their mates based on a similar display. , ... used a bioinspired polarization camera developed by Viktor Gruev, ... Washington University, to make the discovery. His camera has ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Camera developed at WUSTL sheds light on mate choice of swordtail fish 2
... Nov. 9, 2007 Researchers at Childrens Hospital of ... currently underway to study the effectiveness of oral insulin in ... people at risk for the disease. The researchers want ... or delay the onset of type 1 diabetes in relatives ...
... Flip through the 133 page record of the 2006-2007 activities ... and youll see why they recently took home the nations ... toss fundraiser. Youll find the detailed lesson plans that ... to 75 fifth grades at Spreckels elementary school last year. ...
... helping an effort to eradicate malaria, the mosquito-borne disease ... Researchers at the National Institute of Standards and Technology ... a young company create weakened, harmless versions of the ... to create a new type of vaccine that shows ...
Cached Biology News:Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2UC-San Diego Engineering Honor Society wins most outstanding chapter award 2Bug-Zapper: A dose of radiation may help knock out malaria 2
... The Label IT siRNA Tracker Intracellular ... to directly label and deliver siRNA, of ... manner, for in vitro tracking experiments. Subcellular ... expression can be monitored following introduction of ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
... through the extracellular matrix (ECM) is an ... cells initiate invasion by adhering to and ... Proteolytic enzymes, such as MMP collagenases, dissolve ... membrane) surrounding the blood vessels to allow ...
... Cell Invasion Assay is designed to determine ... as a significant barrier to invasion or ... in a convenient, high-throughput, 96-well format. The ... all types of adherent cells such as ...
Biology Products: